Shares of Wave Life Sciences Ltd. WVE rose sharply during Tuesday's session after the company announced interim data from its ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular ...
Some results have been hidden because they may be inaccessible to you